Instrument Inactif

Autres langues CRUCELL

Actions

NL0000358562

Produits pharmaceutiques

Cours en clôture Euronext Amsterdam
- ^EUR	-

31/01/11	Crucell : feu vert de la Commission à l'OPA.
08/12/10	Crucell : en hausse avant l'OPA de Johnosn & Johnson.

Autres langues

28/02/12	Crucell N.V. : JUDGMENT ISSUED IN CRUCELL N.V. BUY-OUT PROCEEDINGS
28/02/12	CRUCELL : JUDGMENT ISSUED IN CRUCELL N.V. BUY-OUT PROCEEDINGS
07/07/11	CRUCELL : Discovers Important New Antibody Against Influenza A
15/03/11	CRUCELL : Intends to Delist Ordinary Shares on NYSE Euronext
08/03/11	CRUCELL : Johnson & Johnson Acquires 98.89% of Issued Crucell Shares as of the End of the Subsequent Offering Period and Crucell Intends to Delist Crucell Ordinary Shares and ADSs
22/02/11	CRUCELL : Johnson & Johnson Completes Tender Offer for Crucell and Declares Offer Unconditional
17/02/11	CRUCELL : Minimum Acceptance Condition Satisfied
08/02/11	CRUCELL : Shareholders Adopt Offer Governance Resolutions and Johnson & Johnson Makes Announcement on U.S. Regulatory Matters
07/02/11	CRUCELL : Reports Fourth Quarter and Full Year 2010 Results
08/12/10	CRUCELL : Johnson & Johnson Launches Recommended Public Offer to Acquire Crucell
30/11/10	CRUCELL : Johnson & Johnson and Crucell Progress Update: Expect to Commence Public Offer Prior to 10 December 2010
09/11/10	CRUCELL : Reports Third Quarter 2010 Results
29/10/10	CRUCELL : Johnson & Johnson and Crucell Provide Progress Update on Preparations for Public Offer
29/10/10	CRUCELL : Notice of Extraordinary General Meeting of Shareholders
28/10/10	CRUCELL : Puts Temporary Hold on Shipments of Quinvaxem and Hepavax-Gene
14/10/10	CRUCELL : to Convene Initial Informational Extraordinary General Meeting of Shareholders to Discuss Johnson & Johnson Offer
06/10/10	CRUCELL : Johnson & Johnson and Crucell Reach Agreement on Intended Public Offer of ?24.75 per Ordinary Share of Crucell
22/09/10	CRUCELL : Aeras and Crucell Announce Phase II Clinical Trial Start in Kenya
17/09/10	CRUCELL : Johnson & Johnson and Crucell in advanced negotiations for an all cash public offer of EUR24.75 per ordinary share of Crucell
17/08/10	CRUCELL : Reports Record Revenues in Second Quarter 2010
11/08/10	CRUCELL : to Release Second Quarter 2010 Results on Tuesday August 17, 2010
11/08/10	CRUCELL : and Harvard (BIDMC) Join Forces with IAVI to Advance AdVac®-based AIDS Vaccine
08/07/10	CRUCELL : Reaches Agreement with Sanofi Pasteur on Programs in the Field of Paediatric and Respiratory Vaccines
24/06/10	CRUCELL : Announces Start of Universal RSV Vaccine Program
04/06/10	CRUCELL : 2010 Annual General Meeting of Shareholders 2009 Financial Statements Adopted; All Resolutions Approved